This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...
Investors lose their appetite for the obesity trade
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...
WBAL-TV15h
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
BMJ5h
Can weight loss drugs like Ozempic treat obesity in children?
GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger people? Katharine Lang reports Obesity in children and adolescents is a ...
Ozempic’s health benefits keep growing, but are the risks worth it?
A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.
Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose risks
Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...
Ozempic and Wegovy: Scientists Uncover New Risks of Popular Weight-Loss “Miracle Drugs”
GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...
The Health Risks and Benefits of Weight-Loss Drugs
The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
Bloomberg L.P.19h
Novo Nordisk A/S
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...